Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
February 1, 2023
New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.
Yale School of Medicine
January 18, 2023
Lung cancer screening may accelerate the shift of the lung cancer stage from an advanced incurable stage toward an early curable disease, which may improve survival.
Journal of Thoracic Oncology
November 2, 2022
A new phase I/II clinical trial shows that repotrectinib had anti tumor activity in participants with the ROS-1-gene.
Medical News Today
October 5, 2022
GSK’s TIM-3 lung cancer drug is moving into a pivotal trial after hitting the mark in the midphase portion of the study.
Fierce Biotech
October 4, 2022
After results from a phase 2 trial, the FDA granted fast track designation to sapanisertib for patients with certain non–small cell lung cancer.
Targeted Oncology
August 8, 2022
In SAVANNAH Phase II trial, Tagrisso + savolitinib showed a 49% objective response rate in lung cancer patients with certain MET biomarkers.
AstraZeneca
March 25, 2021
Sotorasib drug shows meaningful benefits clincally with advanced KRAS G12C mutation in non-small cell lung cancer patients.
CancerNetwork
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.